Combination Therapy with Aldosterone Blockade and Renin-Angiotensin Inhibitors Confers Organ Protection (original) (raw)

• Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.
  Article CAS Google Scholar
• Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
  Article CAS Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–551.
  Article CAS Google Scholar
• Sligl W, McAlister FA, Ezekowitz J, Armstrong PW : Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol 2004; 94: 443–447.
  Article CAS Google Scholar
• Greenberg B : Treatment of heart failure: state of the art and prospectives. J Cardiovasc Pharmacol 2002; 38: 59–63.
  Article Google Scholar
• Remme WJ, Swedberg K : Comprehensive guideline for the diagnosis and treatment of chronic heart failure. Eur J Heart Fail 2002; 4: 11–22.
  Article Google Scholar
• Rocha R, Funder JW : The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970: 89–100.
  Article CAS Google Scholar
• Young M, Head G, Funder JW : Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: 657–662.
  Google Scholar
• Brilla CG, Weber KT : Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992; 120: 893–901.
  CAS Google Scholar
• Funder JW : Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997; 19: 885–899.
  Article CAS Google Scholar
• Sato A, Saruta T : Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303–310.
  Article CAS Google Scholar
• Funder JW : Is aldosterone bad for the heart? Trends Endocrinol Metab 2004; 15: 139–142.
  Article CAS Google Scholar
• Sato A, Suzuki Y, Saruta T : Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17–27.
  Article CAS Google Scholar
• The RALES Investigators : Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study). Am J Cardiol 1996; 78: 902–907.
• Sato A, Saruta T : Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
  Article CAS Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–68.
  Article CAS Google Scholar
• Sato A, Saruta T : Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781–788.
  Article CAS Google Scholar
• van Vliet AA, Donker AJM, Nauta JJP, Verheugt FWA : Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71: 21A–28A.
  Article CAS Google Scholar
• Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD : Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 1259–1265.
  Article CAS Google Scholar
• Fung JWH, Yu CM, Yip G, et al: Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003; 92: 406–410.
  Article CAS Google Scholar
• Pitt B, Reichek N, Willenbrock R, et al: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831–1838.
  Article CAS Google Scholar
• Sato A, Hayashi K, Saruta T : Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44–49.
  Article CAS Google Scholar
• Cohn JN, Anand IS, Latini R, et al, for Valsartan Heart Failure Trial Investigators : Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306–1309.
  Article CAS Google Scholar
• McKlelvie RS, Yusuf S, Mmath P, et al, The RESOLVD Pilot Study Investigators : Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056–1064.
  Article Google Scholar
• Azizi M, Menard J : Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492–2499.
  Article Google Scholar
• Bozkurt B, Agoston I, Knowlton AA : Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003; 41: 211–214.
  Article CAS Google Scholar
• Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D : Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 2003; 327: 1141–1142.
  Article Google Scholar
• Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH : Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147–149.
  Article CAS Google Scholar
• Schepkens H, Vanholder R, Billiouw JM, Lameire N : Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438–441.
  Article CAS Google Scholar
• Tamirisa KP, Aaronson KD, Koelling TM : Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004; 148: 971–978.
  Article CAS Google Scholar